MILESTONE SCIENTIFIC INC.

Milestone Scientific Inc. announced preliminary, unaudited revenue for Q2 2026, expecting approximately $2.8 million, a 21% increase year-over-year. The medical segment showed significant momentum with an anticipated 300% revenue growth compared to Q2 2025. The company also reported progress in reimbursement efforts and international expansion for its dental business, alongside plans to showcase its technology at an upcoming conference.

Milestone Scientific announced strategic governance initiatives, including the appointment of Greg Shilling and Kelly Ann Ulto as independent directors. Benedetta I. Casamento transitioned from Chair of the Board to Executive Chair to drive strategic execution. The company also restructured agreements with founder Leonard Osser, changing his role to Advisor to the CEO with reduced compensation and implementing a share lock-up. Additionally, board member Shanth Thiyagalingam resigned, effective June 30, 2025.

Milestone Scientific Inc. announced its Annual Meeting of Stockholders will be held virtually on July 27, 2026. Key proposals for shareholder vote include increasing authorized common stock from 125 million to 135 million shares and expanding the 2020 Equity Incentive Plan from 11.5 million to 28.75 million shares. Shareholders will also elect five directors, conduct a non-binding advisory vote on executive compensation, and ratify Grassi & Co. as the independent auditors for 2026.

Milestone Scientific Inc. highlighted the growing clinical adoption of its CompuFlo® Epidural System following new peer-reviewed research from the University of Texas Medical Branch. The study, published in Operative Neurosurgery, demonstrated that CompuFlo-guided epidural access during spinal cord stimulator implantation procedures was associated with a 91% reduction in composite complications compared to conventional techniques. This publication further expands the clinical acceptance of CompuFlo technology across a broad range of procedures, with the system now evaluated or utilized in over 40 universities and medical centers globally.

Milestone Scientific reported Q1 2026 financial results, showing a significant reduction in operating loss to $828,000 from $2.0 million in the prior year, and an improved net loss of $840,000. Total revenue remained relatively stable at $2.16 million, despite challenges in shipping orders to the Middle East, with medical business revenue more than doubling year-over-year. The company reaffirmed its 2026 revenue outlook of $9.8 million to $10.2 million, expecting double-digit growth, and completed a $2.15 million financing post-quarter end to strengthen its balance sheet. Milestone Scientific aims to achieve cash flow breakeven in early 2027 and addressed the going concern explanatory paragraph from its 2025 10-K, citing improved liquidity and operational outlook.

Milestone Scientific reported a significant narrowing of its net loss to $0.84 million for Q1 2026, compared to $1.99 million in Q1 2025. The company also completed a private placement in April 2026, generating $2.15 million in gross proceeds to improve its liquidity. Despite these positive developments, product sales slightly decreased to $2.16 million from $2.23 million year-over-year, and the company's recurring losses continue to raise substantial doubt about its ability to continue as a going concern.

Milestone Scientific Inc. announced it will host a conference call on Thursday, May 14, 2026, to discuss its financial results for the first quarter ended March 31, 2026. The call will also cover the company's corporate progress and other developments. Investors can access the call via telephone or a live webcast, with an audio replay available until May 28, 2026.

Milestone Scientific Inc. provided an update on the expansion of its CompuFlo® medical business, highlighting increasing physician utilization and clinical engagement. The CompuFlo® Advisor Program, launched in February 2026, is driving procedural use across multiple Medicare and commercial payer jurisdictions, with active epidural procedures being performed. The company is also expanding its national sales footprint and collaborating with leading academic institutions to support clinical validation and training, all aimed at strengthening its commercial and reimbursement infrastructure.

Milestone Scientific Inc. has dismissed CBIZ CPAs P.C. as its independent registered public accounting firm, effective May 15, 2026. The company has engaged Grassi & Co., CPAs, P.C. as the new independent registered public accounting firm for the fiscal year ending December 31, 2026. While the previous auditor's report for December 31, 2025, contained a

Milestone Scientific Inc.'s Compensation Committee approved a one-time stock option exchange program for its President/CEO and SVP, Global Head of Sales and Marketing. This program repriced eligible options, previously ranging from $0.46 to $0.50 per share, to a reduced exercise price of $0.31 per share, aligning with the closing price on April 30, 2026. The company also approved the grant of performance-based restricted stock units (PRSUs) to certain officers, with a total aggregate pool of 17,234,635 shares, subject to stockholder approval and achievement of performance milestones over a four-year period.